TB-500
TB500 · Thymosin Beta-4 Fragment · T-Beta-4
TB-500 is a synthetic peptide fragment corresponding to the active region of thymosin beta-4, a naturally occurring 43 amino acid protein involved in cell migration, wound repair, and tissue remodeling. The fragment is centered on the actin-binding domain and retains key regenerative signaling properties of the parent molecule. TB-500 is discussed primarily in the context of soft tissue recovery, angiogenesis, extracellular matrix modulation, and inflammatory pathway regulation. It regulates actin polymerization and F-actin formation, which is the molecular machinery that allows cells to migrate to injury sites. TB-500 also suppresses the NF-kB inflammatory pathway systemically. Its half-life of roughly two days means a single injection distributes repair signals across the entire body, distinguishing it from locally-acting peptides like BPC-157.
Starting dose. 2 to 2.5 mg — Per week is commonly discussed
Can be taken any time of day. No fasting required. Systemic distribution means injection site is less critical than BPC-157.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
TB-500 acts primarily through regulation of actin polymerization and cytoskeletal dynamics. By sequestering G-actin monomers, TB-500 controls the balance between monomeric and filamentous actin, which directly affects cell motility, shape, and migration capacity. This allows repair cells (fibroblasts, endothelial cells, stem cells) to migrate to injury sites more effectively. TB-500 also promotes angiogenesis through new blood vessel formation in damaged tissue, modulates inflammatory cytokine signaling via NF-kB pathway suppression, supports extracellular matrix deposition and remodeling, and influences laminin and fibronectin expression relevant to tissue scaffolding. Unlike BPC-157 which acts primarily locally, TB-500 distributes systemically due to its approximately 2-day half-life, providing whole-body repair signaling from a single injection.
What to expect
Days 1-14: Minimal perceptible changes during the first week or two. TB-500 works through gradual cell migration and tissue remodeling processes that take time to manifest. Some users report subtle improvements in flexibility.
Weeks 2-6: Flexibility and mobility improvements become more noticeable. Joint stiffness begins to decrease. Recovery time between workouts shortens. Users with active injuries report functional improvement.
Weeks 6-12: Cumulative tissue remodeling effects become clearly apparent. Chronic injuries show significant improvement. Connective tissue quality improves. Anti-fibrotic effects manifest in reduced scar tissue stiffness. Reassess protocol goals at 8-12 weeks.
Evidence
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Exact-molecule abstract evidence. ESearch was run and 7 source-candidate PMIDs were EFetch-checked; no usable exact-molecule abstract sentence was found.
Dose/route: 2 to 2.5 mg per week is commonly discussed; SubQ is standard injectable route. Systemic distribution makes injection site less critical than BPC-157.; Once or twice weekly for loading, once weekly for maintenance. No selected live abstract sentence verified this complete regimen.
Mechanism as written in source JSON. No selected live abstract sentence verified the complete mechanism at the card formulation/route and relevant population/model.
Primary safety claim as written in source JSON. No selected live abstract sentence verified the complete safety claim for this exact formulation and route.
The honest take
Hair growth
Thymosin beta-4 has been shown to promote hair follicle stem cell migration and differentiation in animal models. Anecdotal human reports of improved hair growth exist. Not a validated hair loss treatment.
Animal studies show thymosin beta-4 promotes cardiac repair post-myocardial infarction by activating epicardial progenitor cells. This is preclinical data and does not support cardiac treatment claims in humans.
TB-500's tissue remodeling and anti-fibrotic properties are discussed in longevity contexts. No human anti-aging data exists. Monitoring only.
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Documented together
Keep separate
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Side effects & safety
Commonly reported
- Generally well tolerated
- Mild injection site redness or swelling
- Occasional headache, particularly during loading phase
- Transient fatigue in some users during first few days
Less common & notes
- Some users report a temporary flu-like feeling during the first week, possibly related to immune system modulation (thymosin beta-4 has immune-active properties).
- Rare reports of lightheadedness.
- Any signs of unusual swelling, persistent headache, or unexpected immune changes should prompt reassessment.
- TB-500 is on the WADA prohibited list.
- Long-term human safety data is not established.
Pharmacokinetics
SubQ
Cell migration and tissue repair signaling persists; supports weekly dosing
Enzymatic degradation (ubiquitous intracellular proteases)
Storage. Store unreconstituted vials frozen (-20C) or refrigerated (2-8C), dry, and protected from light. After reconstitution with BAC water, refrigerate at 2-8C. Stable for 28-30 days when stored properly. Do not freeze after reconstitution. Minimize repeated temperature cycling and needle punctures. Inspect before each use for particles, haze, or discoloration.
Regulatory status
WADA prohibits thymosin beta-4 and its fragments including TB-500 under S2 Peptide Hormones. FDA does not approve TB-500 for any human use. FDA classifies it as Category 2 for compounding purposes. Available through research chemical channels. Regulatory status should be verified against current governing body rules before use.
Put it to work
Calculate, log & track
Open TB-500 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open TB-500 in the app →Go deeper
The guide & community
The complete TB-500 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗